Since the first biopharmaceutical market approval in 1982, the biopharma industry has expanded rapidly. Advances in cell culture productivity, evolving regulatory frameworks, and Quality by Design–driven development have transformed how complex biological drugs are developed, manufactured and formulated.
Biopharmaceuticals are medicinal products derived from biological sources such as living cells, bacteria or microorganisms. Unlike traditional small-molecule drugs, biopharma products require highly controlled upstream and downstream processes to preserve product quality, safety and efficacy throughout development and manufacturing.
Across the entire biopharma value chain—from gene expression to final dosage form—process control and excipient selection play a critical role.
Biopharma Versus Traditional Pharmaceutical Manufacturing
Biopharmaceutical manufacturing differs fundamentally from traditional pharmaceutical production. While conventional drugs are chemically synthesised, biopharma products are generated through biological systems that are inherently sensitive to environmental and process conditions.
As a result, biopharma development places strong emphasis on:
- Process robustness and reproducibility
- Tight control of biological variability
- Selection of high-purity, regulatory-compliant excipients
- Integrated upstream and downstream process design
These requirements make excipients and process aids essential not only in the final drug product, but throughout bioprocessing.
Upstream Process Development: Optimising Culture Scale and Yield
Upstream processing includes all activities related to the growth and maintenance of living cells. This encompasses cell line development, media preparation, cell culture or fermentation, and bioreactor operation.
From the master cell bank to biomass production, culture media composition directly impacts cell viability, productivity and product quality. The choice of media components must support optimal growth while maintaining process stability across scale-up.
Optimised upstream processing enables:
- Higher culture yields
- Improved batch consistency
- Enhanced control of critical quality attributes
Foam Control: A Critical Requirement in Upstream Biopharma Processing
Foam formation is a frequent and challenging phenomenon in upstream biopharmaceutical manufacturing. High aeration rates, shear forces and nutrient-rich media promote foam generation in both cell culture and microbial fermentation.
If unmanaged, foam can:
- Reduce oxygen transfer efficiency
- Increase contamination risk
- Disrupt bioreactor operation
- Compromise batch-to-batch consistency
As biopharma processes evolve toward higher titers and more sensitive expression systems, reliable foam control becomes essential for safeguarding productivity and process integrity.
Foam Management for Consistent Bioprocessing
Effective foam control solutions must combine performance, biocompatibility and regulatory compliance. Antifoams used in biopharma must perform at low dosages, remain stable under sterilisation conditions and minimise interference with downstream purification.
Silicone-based and emulsion antifoams are widely used to maintain stable culture conditions across both stainless-steel and single-use bioreactors. Selecting the appropriate antifoam technology helps reduce processing disruptions while preserving oxygen transfer and microbial performance.
Enabling Regulatory Confidence in Upstream Processing
Beyond performance, foam control agents used in biopharma must meet stringent regulatory and quality requirements. Autoclavable, GMP-manufactured antifoams that are easy to remove during downstream purification support both operational efficiency and regulatory compliance.
By integrating appropriate foam control strategies into upstream processes, manufacturers can improve yields, reduce operational risk and maintain consistency across development and commercial production.
Downstream Process Development: Purification and Stabilisation
Downstream processing determines the purity, safety and efficacy of the final biopharmaceutical product. It includes all chemical and physical separation steps required to isolate and purify the drug substance.
Typical downstream operations include:
- Cell harvesting by centrifugation or filtration
- Chromatography-based purification
- Ultrafiltration and diafiltration
At the end of downstream processing, excipients are often added to stabilise the drug substance during intermediate storage and preparation for formulation.
Common excipient functions include:
- Salts to control protein solubility and precipitation
- Sugars for stabilisation and cryoprotection
- Buffers to maintain pH
- Amino acids to reduce aggregation
Formulation Step: Lyophilisation
Lyophilisation, or freeze-drying, is widely used to preserve sensitive biopharmaceutical products. The process removes water under vacuum while maintaining structural and chemical stability.
Lyophilisation is inherently stressful for biological systems, making cryoprotectants and lyoprotectants essential. These excipients stabilise cell membranes and biomolecules throughout freezing and drying.
The key stages of lyophilisation include:
- Freezing, where ice crystal formation depends on formulation composition
- Primary drying, during which ice sublimates under controlled temperature and pressure
- Secondary drying, removing bound water to achieve long-term stability
The glass transition temperature (T’g) of the formulation defines the stability limits of the freeze-concentrated system.
Lyoprotectant Selection and Process Efficiency
Lyoprotectants play a decisive role in freeze-drying performance. Sugars such as trehalose dihydrate are widely used due to their ability to increase glass transition temperature compared to alternatives such as sucrose.
A higher T’g allows:
- Faster primary drying
- Lower energy consumption
- Reduced risk of cake collapse
At production scale, even small differences in T’g can translate into significant energy savings and improved process robustness.
Final Formulation: Fill and Finish
Fill and finish represents the final stage of biopharmaceutical manufacturing. During this step, the drug product is:
- Formulated to final pH, viscosity and dosage
- Aseptically filled into sterile containers
- Sealed, labelled and packaged for distribution
This stage requires ultra-pure excipients, as injectable and sterile products are subject to extensive regulatory and quality testing prior to release.
Buffers, stabilisers, antioxidants and solubility enhancers are commonly used to ensure product stability, safety and shelf life.
Supporting Biopharma from Development to Commercialisation
Across upstream processing, downstream purification and final formulation, biopharma manufacturing relies on precise excipient selection and process control.
By combining technical expertise, regulatory knowledge and reliable ingredient supply, biopharma partners can support manufacturers in delivering safe, effective and innovative therapies to patients worldwide.